XLO: Houvras Yariv discloses securities transactions

By AlphaYouPublished Oct 2, 2026Form 4

Stocks in this disclosure

Reported activity

Houvras Yariv

Reporting filer

Houvras Yariv reported Grant or award in Xilio Therapeutics, Inc.: 105000 units of Stock Option (right to buy) (derivative), dated 2026-10-01. The full Form 4 contains 1 transaction entry.

Disclosed: Oct 2, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Stock Option (right to buy) (derivative)	Houvras Yariv	2026-10-01	A	Grant or award	105000	0	105,000	1 day	Filed terms security Title: Stock Option (right to buy) conversion Or Exercise Price: 8.91 transaction Date: 2026-10-01 transaction Form Type: 4 transaction Code: A equity Swap Involved: false transaction Shares: 105000 transaction Price Per Share: 0 transaction Acquired Disposed Code: A id: F1 expiration Date: 2036-09-30 underlying Security Title: Common Stock underlying Security Shares: 105000 shares Owned Following Transaction: 105000 direct Or Indirect Ownership: D

Stock Option (right to buy) (derivative)

Owner: Houvras Yariv
Date: 2026-10-01
Code: A
Action: Grant or award
Quantity: 105000
Price: 0
Following holdings: 105,000
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Stock Option (right to buy)
conversion Or Exercise Price: 8.91
transaction Date: 2026-10-01
transaction Form Type: 4
transaction Code: A
equity Swap Involved: false
transaction Shares: 105000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F1
expiration Date: 2036-09-30
underlying Security Title: Common Stock
underlying Security Shares: 105000
shares Owned Following Transaction: 105000
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Houvras Yariv: CHIEF MEDICAL OFFICER.
F1: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Stock Option (right to buy) (derivative)

Houvras Yariv

2026-10-01

Grant or award

105000

105,000

1 day

Filed terms

security Title: Stock Option (right to buy)
conversion Or Exercise Price: 8.91
transaction Date: 2026-10-01
transaction Form Type: 4
transaction Code: A
equity Swap Involved: false
transaction Shares: 105000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F1
expiration Date: 2036-09-30
underlying Security Title: Common Stock
underlying Security Shares: 105000
shares Owned Following Transaction: 105000
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Houvras Yariv: CHIEF MEDICAL OFFICER.

F1: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.